|
Sep 25
|
Medigene AG Expands Protection of its KRAS Library with Filing of New Patent Application Supporting MDG2021
|
|
Aug 29
|
Medigene AG Secures Two Additional Patents for Technologies in Its End-to-End Platform
|
|
Aug 28
|
Medigene to Present at Upcoming Investor Conferences
|
|
Aug 26
|
Medigene AG implements announced 2:1 share capital reduction and consolidation of the shares effective August 29, 2024
|
|
Jun 24
|
Medigene Reports Results of Annual General Meeting
|
|
Jun 21
|
Medigene to Present at the Cell and Gene Therapy In-Depth Focus Summit 2024
|
|
Jun 20
|
Medigene AG Announces Lead Selection for MDG2021, Expanding TCR-T KRAS Library Targeting Solid Tumors
|
|
May 2
|
Medigene AG Expands Patent Portfolio with European Patent Grant for its NY-ESO-1 – targeted T Cell Receptor
|
|
May 2
|
Medigene Presents Superior TCR-T Cell Functionality by Inclusion of a Costimulatory Switch Protein
|
|
Dec 19
|
Medigene AG to attend at the 42nd Annual J.P. Morgan Healthcare Conference
|
|
Aug 10
|
Medigene AG to report Second Quarter and Six Months 2023 Financial Results and Corporate Update on August 17, 2023
|